Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04842747 · ClinicalTrials.gov registry record · Phase 3
VERU-111 in the Treatment of SARS-Cov-2 Infection by Assessing Its Effect on the Proportion of Patients Who Die on Study
A Phase 3 study of SARS-CoV Infection, sponsored by Veru.
- Completed
- Registry status
- Phase 3
- Development phase
- 204
- Enrollment target
- 20
- Study locations
NCT04842747 is a Phase 3 study of SARS-CoV Infection that has completed, run by Veru. The registered enrollment target is 204 participants, below the 3,492-participant average among 12 other SARS-CoV Infection trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT04842747, a Phase 3 study of SARS-CoV Infection, has completed, sponsored by Veru.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 204 participants
- Enrollment target
- 20
- Study locations
Study Summary
To demonstrate the efficacy of VERU-111 in the treatment of SARS-Cov-2 Infection by assessing its effect on the proportion of patients who die on study (prior to Day 60).
Conditions Studied
Interventions
- DRUG VERU-111
Study Locations (20)
New Jersey
- Inspira Medical Center Mullica Hill - Mullica Hill
- Holy Name Medical Center, Institute for Clinical Research - Teaneck
- Inspira Medical Center - Vineland
Tennessee
- The Stern Cardiovascular Foundation, Inc. - Germantown
- Regional One Health - Memphis
- North Knoxville Medical Center - Powell
California
- Velocity Clinical Research - Chula Vista
- Velocity Clinical Research - San Diego - La Mesa
Florida
- Westchester General Hospital, Research Department - Miami
- James A. Haley Veterans Hospital - Tampa
Minnesota
- Methodist Hospital - Saint Louis Park
- Regions Hospital - Saint Paul
North Carolina
- University of North Carolina - Chapel Hill
- Atrium Health Carolinas Medical Center - Charlotte
Texas
- HD Research (Memorial Hermann - Memorial City Medical Center) - Houston
- HD Research (Memorial Hermann Southeast Hospital) - Houston
Arizona
- Honor Health - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 204 participants |
| Start Date | 2021-05-18 |
| Est. Completion | 2022-07-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04842747
The ClinicalTrials.gov registry entry for NCT04842747 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 204 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,492-participant average among 12 other SARS-CoV Infection trials with a reported enrollment target (94% lower). The listed sponsor is Veru, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with SARS-CoV Infection appearing as the primary indexed condition, and to 1 intervention - of which VERU-111 is the first listed.
NCT04842747 reports 20 study locations spanning 11 distinct geographic areas - top geographies include New Jersey, Tennessee, California.
Frequently Asked Questions
What is clinical trial NCT04842747 about?
NCT04842747 is a clinical study titled "VERU-111 in the Treatment of SARS-Cov-2 Infection by Assessing Its Effect on the Proportion of Patients Who Die on Study". To demonstrate the efficacy of VERU-111 in the treatment of SARS-Cov-2 Infection by assessing its effect on the proportion of patients who die on study (prior to Day 60).
What is the current status of trial NCT04842747?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 204 participants. The study started on 2021-05-18. Estimated completion is 2022-07-06.
What conditions does trial NCT04842747 study?
This clinical trial studies the following conditions: SARS-CoV Infection.
What interventions are being tested in trial NCT04842747?
The interventions under investigation include: VERU-111 (DRUG).
Who is sponsoring clinical trial NCT04842747?
This trial is sponsored by Veru, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04842747 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for SARS-CoV Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2
COMPLETED · Phase 3
-
Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease
COMPLETED · Phase 3
-
COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)
COMPLETED · Phase 3
-
Imaging Immune Activation in COVID-19
RECRUITING · Phase 2
-
Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19
RECRUITING · Phase 2
-
KIDney Injury in Times of COVID-19 (KIDCOV)
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.